Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.

International journal of molecular sciences - 3 Dec 2024

Li Luyuan, Hashemi Lily, Eid Josiane, Tao Wensi, Campoverde Leticia, Yu Amy, Farooqi Ammad Ahmad, Al-Ali Hassan, D'Amato Gina, Hornicek Francis, Duan Zhenfeng, Lohse Ines, Trent Jonathan

Abstract excerpt

The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therapies are lacking. Isocitrate dehydrogenase (IDH) mutations represent a potential therapeutic target, but IDH inhibitors alone have shown limited clinical efficacy to date....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Chondrosarcoma

Share to Drug Screening Assays, Antitumor

Share to Drug Synergism

Share to High-Throughput Screening Assays

Share to Isocitrate Dehydrogenase

Source

Open in PubMed Open full text

Identifiers

PMID: 39684713
DOI: 10.3390/ijms252313003
PMCID: PMC11641203

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation.PMID 39684713Read ↗

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaSemantic proximity Read ↗

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?Semantic proximity Read ↗

Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.Semantic proximity Read ↗

Novel therapeutic approaches in chondrosarcoma.Semantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcomaSemantic proximity Read ↗

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma.Semantic proximity Read ↗

Molecular oncogenesis of chondrosarcoma: impact for targeted treatmentSemantic proximity Read ↗

A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.Semantic proximity Read ↗

IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells.Semantic proximity Read ↗

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.Semantic proximity Read ↗

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in ChondrosarcomaSemantic proximity Read ↗

IDH Mutations in Chondrosarcoma: Case Closed or Not?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.